Amiodarone Hydrochloride Patent Expiration
Amiodarone Hydrochloride was first introduced by Wyeth Pharmaceuticals Llc
Amiodarone Hydrochloride Patents
Given below is the list of patents protecting Amiodarone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nexterone | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Baxter Hlthcare |
| Nexterone | US10117951 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US10177951 | Method For Determining Reserved Tones And Transmitter For Performing Papr Reduction Using Tone Reservation | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US7635773 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US9200088 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Baxter Hlthcare |
| Nexterone | US6869939 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
May 04, 2022
(Expired) | Baxter Hlthcare |
Amiodarone Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Amiodarone Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | OHSU Knight Cancer Institute | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |